Keryx Biopharmaceuticals, Inc. Announces Upcoming Poster Presentations of Zer bi13250980 NEW YORK, November 9, 2011 /PRNewswire/ Keryx Biopharmaceuticals, Inc. today announced that two abstracts highlighting potential cost savings based on clinical observations from clinical trials of Zerenex(TM) (ferric citrate) have been ?..

Keryx Biopharmaceuticals, Inc. Announces Upcoming Poster Presentations of Zer bi13250980 NEW YORK, Nov. 9, 2011 /PRNewswire/ -- Keryx Biopharmaceuticals, Inc. (Nasdaq: KERX) today announced that two abstracts highlighting potential cost savings based on clinical observations from clinical trials of Zerenex? (ferric citrate) have been accepted for presentation at..

Posters for London 2012 Olympics unveiled bi13250980 A nude Paralympic cyclist, an abstract take on Big Ben and two birds kissing

Keryx Biopharmaceuticals, Inc. Announces Upcoming Poster Presentations of Zer bi13250980 NEW YORK, November 9, 2011 /PRNewswire/ Keryx Biopharmaceuticals, Inc. today announced that two abstracts highlighting potential cost savings based on clinical observations from clinical trials of Zerenex(TM) (ferric citrate) have been ?..

Keryx Biopharmaceuticals, Inc. Announces Upcoming Poster Presentations of Zer bi13250980 NEW YORK, Nov. 9, 2011 /PRNewswire/ -- Keryx Biopharmaceuticals, Inc. (Nasdaq: KERX) today announced that two abstracts highlighting potential cost savings based on clinical observations from clinical trials of Zerenex? (ferric citrate) have been accepted for presentation at..

Aeterna Zentaris Presents Encouraging Preclinical Data for Disorazol Z (AEZS- bi13250980 Aeterna Zentaris Presents Encouraging Preclinical Data for Disorazol Z (AEZS-137) at AACR-NCI-EORTC Conference..

Femprox(R) Phase III Clinical Data From Apricus Biosciences Chosen for a Pres bi13250980 SAN DIEGO -- Apricus Biosciences, Inc. ("Apricus Bio" or the "Company") announced today the acceptance of an abstract entitled, "Age Group Analysis of a Randomized, Double-blind, ..

Press Release bi13250980 Asuragen, Inc

YM BioSciences to Report Updated Phase I/II Data for CYT387 at ASH 2011 bi13250980 YM BioSciences to Report Updated Phase I/II Data for CYT387 at ASH 2011..

Galapagos to present results for selective JAK1 inhibitor rheumatoid arthr bi13250980 GLPG0634 preclinical/Phase I presentation tomorrow at ACR 2011 Mechelen, Belgium; 7 November 2011- Galapagos NV (Euronext: GLPG) announced today that disclose topline results from the Phase ..

DGAP-News: Femprox(R) Phase III Clinical Data From Apricus Biosciences Chosen bi13250980 Apricus Biosciences, Inc. 14.11.2011 15:47 SAN DIEGO, 2011-11-14 15:47 CET (GLOBE NEWSWIRE) -- Apricus Biosciences, Inc. ('Apricus Bio' or the 'Company') (Nasdaq:APRI) announced today the acceptance of an abstract entitled, 'Age Group Analysis of a..

Octagon Clinical Expert Receives CDISC International Interchange Award bi13250980 Hanming Tu Wins CDISC International Interchange Session..

Adult Babies Wearing Diapers - Home